NCT05907382

Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003002 in Single and Multiple Ascending Dose Randomized，Doubled-blind Phase 1 Study in Healthy Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Jemincare · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Safety, tolerability, pharmacokinetics, and pharmacodynamics of JMKX003002 in single and multiple ascending dose randomized，doubled-blind phase 1 study in healthy subjects

Detailed description

Pharmacokinetic (PK) parameters, Pharmacodynamics

Conditions

• Safety and Tolerability

Interventions

Type	Name	Description
DRUG	JMKX003002 will be administered orally	oral once
DRUG	JMKX003002 will be administered orally	oral once
DRUG	JMKX003002 will be administered orally	oral once
DRUG	Placebo in Cohorts 1 to 5	oral once
DRUG	Placebo in 2 Cohorts	oral once

Timeline

• Start date: 2023-05-09
• Primary completion: 2023-12-01
• Completion: 2024-03-01
• First posted: 2023-06-18
• Last updated: 2023-06-18

Locations

1 site across 1 country: China